All analyses
AI analysis

Hemas Holdings Ltd.: research report

Moderately undervaluedbullishNov 14, 2026

The evidence points bullish because revenue and operating profit kept growing while the shares screen moderately undervalued. The catch is that net profit fell as finance costs rose.

Today's public report is ready. The next one can be generated tomorrow. Add a focus below for your own private research.

Reports without a focus are public, one per stock per day. Generation usually takes about 15 minutes, and we'll notify you when it's ready.

Why bullish

  • September-quarter revenue rose 17.1% and operating profit increased 8.1%, showing that core operations still expanded despite margin pressure.
  • FY2026 return on equity was 15.7%, while the group held LKR 11.6 billion of net cash at the March year-end.

Against this. September-quarter net profit fell 1.7% as LKR 1.7 billion of charges below operating profit absorbed much of the operating result.

Operating margin
10.0%sector 9.7%
from 10.8% a year earlier
Net margin
5.6%sector 3.0%
from 6.7% a year earlier, revenue +17.1%
Return on equity
15.0%
twelve months to Sep 30, 2026, unaudited
P/E
11.4sector 14.2
earnings Rs 2.87 per share, year to Sep 2026
P/B
1.71sector 1.20
book Rs 19.22 per share
Dividend yield
3.05%sector 2.08%
34.8% of earnings paid out

Current figures, updated daily from filings to Sep 30, 2026. The report below was written on Nov 14, 2026. Sector figures are the median of 22 listed companies in the same sector.

Overview

Hemas is a diversified Sri Lankan group spanning healthcare, consumer brands, mobility, leisure, travel, aviation and logistics. The latest quarter showed a clear split: sales and operating profit advanced, but higher costs after operating profit left net earnings slightly lower. Its completed majority investment in Kenya's Twiga adds an East African consumer platform, although the disclosed terms do not quantify the acquired business's revenue or profit contribution.

Price performance

At LKR 33.10 on 13 November 2026, the share gained 8.8% over one month, behind the ASPI's 10.3%, and fell 7.5% over one year against a 4.7% ASPI decline. The relative record is therefore mixed rather than a broad market-like move.

The price sits 61.2% of the way from its 52-week low to high. Recent volatility was quieter than its own one-year norm, while 20-day volume was above the preceding 60-day pace. The three-year record shows two falls of 15% or more, the deepest 24%, which took seven months to recover. Median daily turnover was LKR 5.2 million, and a LKR 1 million order is about 19% of what trades on a typical day, a noticeable part of a day's trading.

Valuation

At 11.1 times P/E, the market pays LKR 11.10 for every LKR 1 of trailing profit, below the diversified-holdings median of 14.8 times. P/B is 1.72 times, or LKR 1.72 for each LKR 1 of net assets, above the sector median of 1.18 times; FY2026 ROE of 15.7% helps explain why the shares do not trade at the sector's book multiple.

The 3.0% dividend yield is supported by FY2026 dividends of LKR 1.00 per share, up from LKR 0.90 in FY2025. P/E is cheaper than 62% of days since January 2019, but P/B is more expensive than 77% of days over that record. A buyer at this price relies on the latest quarter for 23.4% of trailing EPS; if that quarter had retained its year-ago net margin, P/E would be 10.6 times rather than 11.1 times.

News and sentiment

Direct coverage was normal, with 25 material articles over 90 days split between 12 positive, 10 negative and three neutral. The 6 November results coverage consistently reported strong September-quarter sales growth but lower earnings as finance costs rose.

Hemas reported on 6 November that it had completed the acquisition of a 75% stake in Kenya's Twiga Stationers and Printers for US$16.2 million. This extends the Consumer Brands footprint into East Africa, but Twiga's revenue and earnings were not disclosed, so its contribution cannot yet be sized against Hemas's operations. A LKR 0.25 first interim dividend has a confirmed 16 November 2026 ex-date.

Financials

September-quarter revenue rose 17.1% to LKR 37.8 billion, while operating profit increased 8.1% to LKR 3.8 billion. Gross margin was 29.7% against 32.8% a year earlier, operating margin was 10.0% against 10.8%, and net margin was 5.6% against 6.7%. Each measure was middling against the group's prior September quarters, so the margin compression is not an extreme result in its own comparable record.

Net profit slipped 1.7% to LKR 2.1 billion even though operating profit grew. Charges below operating profit took LKR 1.7 billion, meaning finance costs, tax and other non-operating items absorbed a larger share of the operating result. This is why the profit behind the share price grew more slowly than sales.

The latest balance sheet reported LKR 59.6 billion of total equity and 3.0 billion shares, the same share count used for current book value. The May 2025 one-for-five share subdivision mechanically changed historic per-share figures, so earnings performance is better judged from absolute profit and revenue.

Risks

The main risk is the sharp rise in funding needs after the March year-end. Total debt was LKR 18.4 billion at September, versus LKR 6.1 billion at March, while finance cost rose to LKR 464 million from LKR 186 million a year earlier. News coverage attributed the increase to working-capital borrowings and the Twiga acquisition, and this explains why operating growth did not translate into higher net profit.

The latest annual balance sheet was nevertheless conservatively financed: gearing, meaning debt against owners' equity, was 10.8%, down from 15.2%, and operating profit covered interest 13.8 times, up from 9.1 times. The current ratio was 1.72 times versus 1.64 times, meaning short-term assets including inventories and receivables exceeded bills due within a year. Cash conversion was 0.83 times, below 0.98 times, so not all annual operating profit arrived as cash.

Healthcare accounts for 62% of reported segment revenue and consumer retail 38%. The sector backdrop includes higher inflation and fuel costs, which are relevant cost and demand risks for those businesses, but the data does not establish a direct effect on Hemas.

Outlook

As at 14 November 2026, the next decisive update is the December 2026 interim filing, expected between 6 and 14 February 2027. It will show whether the September sales rebound and the higher borrowing burden persisted after the Twiga acquisition, and will supersede the financial figures used here.

The confirmed LKR 0.25 interim dividend goes ex-dividend on 16 November 2026 and is payable on 4 December 2026. The available data cannot yet separate Twiga's earnings contribution from the wider Consumer Brands result.

About this report. Generated on Nov 14, 2026 from market data up to Nov 13, 2026, 25 material news articles over 90 days and financials to Sep 30, 2026, and scored 64 of 100 on value (moderately undervalued) when it was written. Every figure is drawn from EquityLK's own data on this company. AI research can contain errors, so treat it as a starting point, not investment advice.

Previous reports